.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
Cerilliant
Johnson and Johnson
US Department of Justice
Federal Trade Commission
Teva
McKesson
Chubb
Cipla

Generated: December 16, 2017

DrugPatentWatch Database Preview

LANTUS SOLOSTAR Drug Profile

« Back to Dashboard

When do Lantus Solostar patents expire, and what generic alternatives are available?

Lantus Solostar is a drug marketed by Sanofi Aventis Us and is included in one NDA. There are sixteen patents protecting this drug.

This drug has one hundred and ninety-five patent family members in twenty-seven countries and forty-two supplementary protection certificates in twelve countries.

The generic ingredient in LANTUS SOLOSTAR is insulin glargine recombinant. There are thirty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin glargine recombinant profile page.

Summary for LANTUS SOLOSTAR

Drug patent expirations by year for LANTUS SOLOSTAR

Pharmacology for LANTUS SOLOSTAR

Ingredient-typeInsulin
Drug ClassInsulin Analog

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► Subscribe► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Sanofi Aventis UsLANTUS SOLOSTARinsulin glargine recombinantINJECTABLE;INJECTION021081-002Apr 27, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: LANTUS SOLOSTAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,070,727Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,623,190Pen-type injector► Subscribe
9,028,454Drive mechanisms suitable for use in drug delivery devices► Subscribe
7,553,299Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,574,198Drive mechanisms suitable for use in drug delivery devices► Subscribe
9,205,197Drug delivery device dose setting mechanism► Subscribe
8,663,175Drive mechanisms suitable for use in drug delivery devices► Subscribe
8,021,345Pen-type injector► Subscribe
7,918,833Pen-type injector► Subscribe
8,876,782Drive mechanisms suitable for use in drug delivery devices► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: LANTUS SOLOSTAR

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2004078239► Subscribe
Israel214157► Subscribe
Portugal2263723► Subscribe
Austria497398► Subscribe
Australia2004216827► Subscribe
Austria474614► Subscribe
Cyprus1114098► Subscribe
Austria422166► Subscribe
Slovenia2263724► Subscribe
China100443128► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: LANTUS SOLOSTAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0885961/01Switzerland► SubscribePRODUCT NAME: INSULIN GLULISIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57013 02.05.2005
C0009France► SubscribePRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
2/2005Austria► SubscribePRODUCT NAME: INSULIN GLULISINE
C/GB05/024United Kingdom► SubscribePRODUCT NAME: INSULIN GLULISINE OR A PHYSIOLOGICALLY TOLERABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/04/285/001 - 020 20040929
2013000062Germany► SubscribePRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND INSULIN ASPART IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/806/001 EU/1/12/806/004-005 EU/1/12/806/007-008 20130121
2004005Lithuania► SubscribePRODUCT NAME: INSULIN DETEMIR
2017000040Germany► SubscribePRODUCT NAME: SCHNELL-WIRKENDES INSULIN ASPART; REGISTRATION NO/DATE: EU/1/16/1160 20170109
13/34Ireland► SubscribePRODUCT: INSULIN DEGLUDEC IN ALL ITS FORMS AS THEY ARE PROTECTED BY THE BASIC PATENTS; REGISTRATION NO/DATE: IRELAND EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 / 21/01/2013
60026Netherlands► SubscribePRODUCT NAME: INSULINUM LISPRUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/96/007/001 - EU/1/96/007/003 19960430
91022-0Sweden► SubscribePRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo
Chubb
Fish and Richardson
Dow
Deloitte
US Department of Justice
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot